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Contents Foreword
The Cross-Party Group (CPG) on Heart Disease and Stroke is formed of MSPs 
(Members of the Scottish Parliament), clinicians, third sector organisations and 
individuals with an interest in heart disease or stroke.
The group meets regularly at the Scottish Parliament 
to debate and discuss relevant issues. Atrial fibrillation 
was identified as a priority area and therefore a panel 
was convened to produce this report. Working in such 
a collaborative way has allowed the report to benefit 
from a range of expertise and created a synergy that 
could be an exemplar for future policy work.
Atrial fibrillation is one of the most common types of 
irregular heart rhythm, with 96,000 people in Scotland 
diagnosed with the condition. People with atrial fibrillation 
are at a significantly increased risk of having a stroke, which 
can have a devastating personal impact for the individual 
and their family. The impact of stroke on health and social 
care system resources in Scotland is also significant, with 
atrial fibrillation related strokes costing significantly more 
than strokes from other causes.
There are many local examples of excellent care, good 
practice and innovation for people living with atrial 
fibrillation. However, many people living in Scotland have 
this potentially devastating condition without even being 
aware of it, and many more, even after their diagnosis,  
are not receiving the appropriate treatment and support  
to reduce their risk of stroke.
The CPG undertook this inquiry to better understand the key 
issues and how to drive forward positive change. We would 
like to thank all of those who took the time to contribute to 
the inquiry — whether that was through responding to the 
consultation, by sharing the consultation with their 
networks or taking part in a roundtable session in 
Parliament. In particular we would like to extend our 
gratitude to those people who were kind enough to 
share with us their personal experiences of living with 
atrial fibrillation.
We would also like to draw attention to the efforts invested 
in this project by members of the advisory panel for this 
inquiry. They dedicated significant time and provided 
invaluable advice, which was greatly appreciated.
The recommendations in this report will drive forward 
change in relation to atrial fibrillation in Scotland, and 
act as a catalyst towards improving the outcomes and 
experiences of people with this condition. Creation of this 
report is only the first step. The CPG and the advisory panel 
are keen to build on the momentum created by the report 
and work collaboratively with the Scottish Government and 
NHS Scotland to make a difference to the lives of people 
living with atrial fibrillation, their families and carers.
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Advisory Panel Summary of Recommendations
The Scottish Government should
Encourage targeted AF case-finding programmes for those most at risk 
(age over 65 years, those with previous stroke and those with existing 
cardiovascular risk factors).
 Work with the relevant National Advisory Committees to address the 
shortage of cardiac physiologists working within Scotland.
Invest in the use of proven technologies within clinical practice to  
detect AF.
 Work with stakeholders in primary and secondary care to create a clear  
and consistent clinical pathway for people diagnosed with AF.
 Actively promote and support health boards to implement specialised AF 
services to facilitate accurate diagnosis; to ensure prompt, appropriate 
anticoagulation and to ensure patient-centred management.
Imbed consistent and effective data capture, ensuring integration across 
clinical boundaries of primary and secondary care and efficient processes  
for linking and accessing these data.
 Support the development and implementation of IT software solutions to 
facilitate case-finding, support therapeutic decisions and allow audit within 
and between practices.
 Ensure that all health care professionals have the necessary information 
about AF to support patients to take part in shared decision making, from  
the point of diagnosis of AF through to long term condition management.
 Work with clinicians, researchers, third sector and people affected by AF to 
find the most effective methods to raise awareness of AF amongst the public.
 Ensure that people with AF and at risk of AF receive relevant, tailored 
information and support, utilising robust and trusted providers such as  
major third sector charities.
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5xIntroductionWHAT IS ATRIAL FIBRILLATION? Atrial Fibrillation (AF) is one of the most common types of irregular heartbeat. In a normal heart the heart’s pumping action is controlled by regular electrical 
messages produced by part of the heart called the sinus node.
AF occurs when additional, irregular electrical messages 
are sent from other places in and around the atria (the 
upper chambers of the heart). These irregular messages 
make the atria quiver or twitch, which is known as 
fibrillation.
Some people will experience symptoms due to their AF. 
These can include palpitations, breathlessness, dizziness, 
fainting or fatigue. People who experience symptoms are 
more likely to seek support from health care professionals 
and as a result are more likely to have access to treatment 
which can reduce their risk of stroke.
However, as many as 40% of people with AF do not 
experience any symptoms at all (this is often called 
asymptomatic AF).1
AF frequently progresses through the following three stages, 
all of which can be present without the person experiencing 
any symptoms and all with an increased risk of stroke;
–  Paroxysmal atrial fibrillation is AF that comes and 
goes. It usually lasts for less than two days but can last 
for up to seven days. The heart reverts back to normal 
rhythm by itself and AF is not there all the time.
–  Persistent atrial fibrillation lasts longer than seven 
days at a time but it is still possible for the heart rate  
and rhythm to return to normal.
–  Permanent atrial fibrillation is there all the time and 
the heart does not return to a normal rhythm.
A significant and devastating complication of all three 
stages of AF is ischaemic stroke. AF increases the risk of 
stroke by five times.2 This is because the irregular activity  
in the atria allows blood to pool in the heart. This blood  
can then form clots which might make their way to the 
brain, causing a stroke. 
Ischaemic stroke happens when the blood supply to part 
of the brain is cut off. Blood carries essential nutrients 
and oxygen to the brain and without it, brain cells can be 
damaged or die. This damage can have different effects, 
depending on which part of the brain is affected. A stroke 
can affect the way someone’s body functions as well as 
impacting how they think, feel and communicate. Strokes 
which occur as a result of AF are more likely to be fatal or 
severely disabling.3 
Even if someone with AF does not experience symptoms, 
their AF still carries a similar risk of stroke compared to 
AF which presents with symptoms4 and so detection of 
asymptomatic AF is important in order that people have the 
opportunity to reduce their risk of stroke through treatment. 
Importantly, the risk of someone with AF having a stroke 
can be reduced by treatment with anticoagulation 
medication. Appropriate use of anticoagulation reduces 
stroke risk in AF by two thirds.5 
While stroke is the most common complication, AF is 
associated with a number of other conditions including 
heart attack and dementia. Less is understood about AF 
and these complications, but recent studies suggest that 
anticoagulant medications can reduce the risk.6 AF is also 
associated with heart failure.7 The relationship between 
the two is only partially understood and is subject to 
ongoing research. It is thought that AF may facilitate the 
development or progression of heart failure in a number  
of ways.8 
RISK FACTORS IN ATRIAL FIBRILLATION 
A number of risk factors are associated with AF, 
including increasing age, high blood pressure, heart 
failure, valvular heart disease, previous heart attack, 
thyroid disease, obesity, diabetes, chronic lung disease, 
sleep apnoea, kidney disease, smoking and excessive 
alcohol consumption.9 
The identification of these risk factors and their prevention 
and management is an important factor in reducing the 
burden of AF. Recent research has shown potential benefits 
for lifestyle changes and risk factor management to have a 
positive impact on the progression of AF.10 
NORMAL ELECTRICAL SIGNALS IN THE HEART
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THE SCALE OF ATRIAL FIBRILLATION 
IN SCOTLAND
AF is one of the most common irregular heart rhythms 
and people over the age of 40 years have a lifetime 
risk of one in four of developing AF.11 Quality Outcome 
Framework (QOF) data (collected from GP practices) 
shows that in 2016, 96,367 people in Scotland had been 
diagnosed with AF.12 However, it is estimated that 2.6% 
of the Scottish population, which is around 145,000 
people, have AF. That would mean that nearly 50,000 
people in Scotland are living with undiagnosed AF, 
putting them in danger of having a stroke.13 
The condition becomes more common with age; therefore 
Scotland’s ageing demographic means that it will likely 
affect higher numbers of the population in future. Indeed, 
it is suggested that rates of AF will more than double by the 
year 2060.14
THE IMPACT OF STROKE IN SCOTLAND
Stroke is the third most common cause of death and a 
leading cause of disability in Scotland. The Information 
Services Division recorded that 8,902 people in 
Scotland had a confirmed stroke in 2015/16.15 The 
Scottish Stroke Care Audit estimates 15,000 people 
in Scotland have a stroke each year.16 This suggests 
that the number of presentations to secondary care 
with stroke and suspected stroke may be much higher. 
Around 124,000 people in Scotland have survived a 
stroke or Transient Ischaemic Attack (TIA).17 Stroke can 
have a massive personal impact for an individual and 
their family.
At a broader level, it also has a large financial impact on 
health and social care services in Scotland, accounting for 
approximately 5% of total NHS costs.18 The economic cost 
of stroke to Scotland in terms of lost employment and the 
cost of support in the community are also significant.
A large UK study which looked at the incidence and outcome 
of AF related strokes showed that 24.2% of acute cerebral or 
peripheral vascular events were related to AF.19 International 
data suggests that at least a third of all ischaemic strokes 
are caused by AF.20 However it is likely that the impact of 
AF with regards to stroke burden will be underestimated 
because, even after stroke, AF can remain undetected.
In a large study of people with known AF, including 94,474 
people who had AF-related strokes, 84% of patients were 
not receiving adequate guideline based treatment at the 
time of the stroke.21 Therefore improved detection, diagnosis 
and appropriate treatment of AF present an opportunity to 
reduce the impact of stroke in Scotland.
POLICY CONTEXT
Many of the risk factors associated with AF are 
common to heart disease and stroke. These are also 
similar for many other long term conditions which 
present challenges to population health in Scotland. 
These population health issues are complex, persistent 
and underpinned by issues such as poor nutrition, 
obesity, physical inactivity and an ageing demographic. 
To tackle these issues, the policy context in Scotland 
is focused on the need for preventative measures. The 
“Christie Commission” highlighted the need for public 
services to shift towards prevention. Similarly the 
“Scottish Government’s 2020 Vision for Health” also 
focuses on prevention.
The solutions to these challenges will be beyond the scope 
of health care systems alone and require the influence of 
wider agendas, policies and programmes. Therefore bold 
political decisions will be needed in the coming years to 
provide solutions to such challenges. 
Treating and preventing stroke is a national clinical priority 
for Scotland. In 2009 the “Better Heart Disease and Stroke 
Care Action Plan”22 was published, followed in 2014 by 
improvement plans for both Heart Disease and Stroke.23,24 
These plans set out the priorities and actions required to 
deliver improved prevention, treatment and care for all 
people in Scotland affected by heart disease and stroke. 
Both highlight the need for improved identification, 
diagnosis and management of AF.
These specific priorities for heart disease and stroke  
sit within a wider Scottish framework which is focused  
on the provision of patient-centred, preventative and 
anticipatory health services, delivered by multi-disciplinary, 
integrated teams. This is seen as a way of better addressing 
the needs of people with long term conditions, while also 
managing the financial pressures that NHS Scotland faces. 
This direction was outlined in the Scottish Government’s 
route map to achieving sustainable quality in the delivery  
of healthcare services across Scotland by 2020.25
The Public Bodies (Joint Working) (Scotland) Act 2014 which 
came into effect in April 2016 requires the integration 
of health and social care and created 31 integration 
partnerships which work across health and social care. These 
authorities now have responsibility for over £8bn of funding 
for local services which was previously managed separately 
by NHS Boards and Local Authorities.
A further key policy agenda of note is “The Modern 
Outpatient: A Collaborative Approach 2017–2020” which 
aims to deliver care closer to the patient’s home, provide 
more person centred care, utilise new and emerging 
technologies, whilst maximising the role of clinicians across 
primary, secondary and community based services.
The Chief Medical Officer in Scotland encourages a concept 
of “Realistic Medicine”. This places the person receiving 
health and care at the centre of decision-making and 
encourages a personalised approach to their care. It has 
core aims of reducing harm and waste, tackling unwarranted 
variation in care, managing clinical risk and innovating to 
improve.
Alongside these shifting priorities for health care there 
remains a need to deal with the ever present challenges 
of rurality and deprivation, both of which are particularly 
pronounced in Scotland and have a significant impact on 
the way in which services can be delivered.
There is also policy recognition that all of this requires  
a co-ordinated approach to appropriate data sharing.  
This means that the right digital culture, skills, processes  
and systems will need to be in place to achieve key health 
policy aims.
It is against this background and with these key policies  
in mind that our recommendations related to the diagnosis, 
initial treatment and further management of AF in Scotland 
have been created. 
96,367
PEOPLE IN SCOTLAND HAVE BEEN 
DIAGNOSED WITH AF
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The Inquiry 
Process
The second step was for the advisory panel to develop a 
consultation tool to gather initial information. This took 
the form of two separate questionnaires; one which was 
relevant to people living with AF and another which was 
relevant to clinicians and organisations with an interest 
in AF. The questions were divided into four key topics 
which were; prevention, diagnosis, treatment and data 
use relating to AF. The questions aimed to allow people 
to share their knowledge, so were largely qualitative  
in nature. 
The consultation ran for 12 weeks from 20th June to 15th 
September 2017. There were 203 responses to the clinical 
consultation and 59 to the consultation for people living 
with AF. The consultation responses were analysed in order 
to identify recurrent themes.
The final step in the inquiry process was the hosting of four 
round table meetings in the Scottish Parliament throughout 
October and November 2017. The round table meetings 
were split into topics similar to those which shaped the 
consultation. These were; diagnosis, treatment, data 
use and a patient round table. 
Around 15 people with expertise in these areas, or those 
who had responded to the inquiry consultation, were  
invited to attend each round table meeting. The discussions 
at these meetings explored, in more depth, the key themes 
that had emerged from the consultation responses and 
helped to further develop the recommendations in  
this report. 
The first step was to approach individuals with knowledge and expertise related  
to AF in order to form an advisory panel to guide the inquiry.
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Section One:
Detection and 
Diagnosis of Atrial 
Fibrillation
BACKGROUND 
AF detection and diagnosis is important in preventing stroke in the first 
instance (primary prevention) and also in the prevention of a further stroke 
(secondary prevention).
I think the big problem is those who are  
undiagnosed, who perhaps don’t have 
many symptoms, aren’t aware that they’ve 
got AF and their risk of stroke, or heart  
failure are very, very much increased. 
Gordon (round table participant)
Detection of AF for primary prevention of stroke: 
Traditionally, the most common method for detecting AF 
is the use of a radial pulse check for 60 seconds. If AF is 
present the pulse may feel irregular. This has been described 
as feeling like Morse code, whereas a normal pulse feels like 
a ticking clock.26 An irregular pulse only suggests that AF 
may be present. Occasional extra beats of the heart can be 
normal and carry no risk but might be mistaken for AF when 
feeling a pulse.
Because pulse checking can be inaccurate, if an irregular 
pulse is detected then a 12 lead Electrocardiograph 
(ECG) needs to be carried out as soon as possible in order 
to confirm the diagnosis. If it is thought that the AF is 
paroxysmal then a longer ECG monitoring period may be 
required (usually 24–48 hours). Although some GP practices 
have ECG machines, often such diagnostic tests require 
referral to a cardiac physiologist to carry out the tests 
and analyse the results.
There is a selection of new technologies which can be used 
to detect possible AF. These technologies are more accurate 
at detecting AF than pulse taking alone.27 Therefore they 
reduce the likelihood of requiring unnecessary tests to 
exclude a diagnosis amongst people who do not have AF.
There are a number of benefits to incorporating technology 
in the quest to improve the detection of AF and indeed, this 
is highlighted in a case study later in the report. Technology 
in this area has advanced rapidly, perhaps more quickly 
than guidelines, research and clinical practice can keep up 
with. While increasingly sophisticated methods of diagnosis 
are welcome, the adoption of new technology must follow 
proper evaluation.
“ ”
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Detection of AF for secondary prevention of stroke:
Diagnosis of permanent or persistent AF following stroke is 
fairly straightforward since detection of AF can be guided 
with a 12 lead ECG which should be routinely performed in 
patients with stroke or TIA.²8
However, detection of paroxysmal AF for those who have 
already had a stroke requires longer ECG monitoring to 
detect AF. Current National Institute for Health and Care 
Excellence (NICE) and European Society of Cardiology (ESC) 
guidelines, recommend at least 24 hour ECG monitoring 
for people who are suspected to have paroxysmal AF.²9 
ESC guidelines also highlight that there is good evidence 
that prolonged ECG monitoring enhances the detection 
of undiagnosed AF, e.g. monitoring for 72 hours after a 
stroke.30 It has been shown that even longer durations 
of monitoring (for a target of 30 days) can significantly 
improve the detection of AF among patients who have 
presented with a stroke, compared to 24 hour monitoring.31
The 2017 Stroke Improvement Programme Report 
introduced national standards for the detection of AF in 
patients who have had a stroke or TIA. All NHS Health 
Boards should have agreed criteria for offering prolonged 
ECG monitoring to patients with ischaemic stroke and 
TIA. Prolonged monitoring should be available to patients 
meeting these local criteria and the results should be 
available within two weeks of the request for prolonged 
monitoring. It was highlighted throughout the inquiry that 
adherence to these criteria was variable across Scotland 
and it would be pertinent for the Scottish Government to 
ensure that all Health Boards adhere to these criteria. This is 
monitored through the Scottish Stroke Improvement Plan. 
It is estimated that as many as one third of people with 
AF are undiagnosed.32 Prompt diagnosis allows people to 
receive anticoagulation treatment which can reduce their 
risk of having a stroke by around two thirds. 
Given the risks associated with AF it is important that we 
consider ways in which we might improve and increase 
detection and diagnosis of this condition. This inquiry 
sought to understand the barriers to doing so which exist  
in Scotland, and identify solutions to overcoming these. 
INQUIRY FINDINGS — DIFFICULTY IN DETECTING AND DIAGNOSING 
ASYMPTOMATIC OR PAROXYSMAL ATRIAL FIBRILLATION
“ I had a stroke at work and on being admitted 
to hospital was diagnosed as having AF by the 
clinical team looking after me.”
Respondents to the consultation shared that it 
is difficult to detect and diagnose AF which is 
asymptomatic or paroxysmal. This is because people 
without symptoms are unlikely to present to a health 
care professional with specific regard to their AF 
and those with paroxysmal AF might not be in AF 
at the time they are undergoing diagnostic checks. 
Asymptomatic AF still carries a similar risk of stroke 
compared to AF which presents with symptoms33  
while the risk of stroke related to paroxysmal AF  
is only slightly lower than that of permanent AF.34  
Both types of AF often require anticoagulation.
Devastatingly, the first time many people with 
asymptomatic AF have their AF detected is when they 
present with a stroke. 
“ I had a stroke at work and on being admitted to 
hospital was diagnosed as having AF by the clinical 
team looking after me.”
We heard from a number of people about how their 
paroxysmal AF made their diagnosis difficult. 
“ It was several years before it could be confirmed on 
ECG because it always came on at night.”
Case-finding to detect asymptomatic and paroxysmal AF 
presents itself as a crucial opportunity to avoid AF related 
strokes and the resulting personal and economic impact 
that these have. 
AF case-finding could be easily carried out in primary 
care, pharmacies or community settings with minimally 
invasive tests (including pulse checks, new single lead ECG 
technologies, or 12 lead ECG for those with the highest 
probability of AF). This would mean that many of the  
harms typically associated with case-finding; such as  
patient discomfort, long waiting times and considerable 
anxiety about the results would be minimal.35 
In particular, the new, single lead ECG devices are much 
more accurate than pulse checks. This means that using 
such technology could reduce the amount of ECGs 
required for people who will not end up with an AF 
diagnosis. Therefore case-finding using these tools could 
be particularly effective and indeed, a number of studies 
have demonstrated that such programmes could be cost 
effective.36,37
Opportunistic case-finding is advocated for people aged 
over 65 years in European AF management guidelines.38 
Discussions at the inquiry round table meeting focusing 
on detection and diagnosis were broadly supportive of 
targeted case-finding with a focus on those people most at 
risk. The categories for targeted case-finding should include 
those over 65 years of age and those with significant risk 
factors for AF including cardiovascular disease, diabetes or 
respiratory disease.
Responses to the inquiry consultation highlighted a recent 
study in Scotland which focused on AF case-finding 
in primary care, using a single lead ECG device. These 
technologies can be hand-held and record an ECG reading.
IT IS ESTIMATED 
THAT AS MANY AS 
ONE 
THIRD 
OF PEOPLE WITH AF  
ARE UNDIAGNOSED
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INQUIRY FINDINGS — DIFFICULTY ACCESSING DIAGNOSTIC SERVICES
Another issue that was highlighted by the consultation 
responses was the variance of access to diagnostic 
services that exists across Scotland. 
“Not all areas have easy access to 12-lead ECG — e.g. in 
Tayside all GP practices have a machine, but in Lothian 
some patients have to attend hospital for an ECG, which 
can be a significant barrier. In Wishaw, patients attend 
hospital for their ECG and it isn’t a barrier because the 
District General Hospital is in the town, so there is a very 
varied picture across Scotland.” 
This issue was discussed in more detail at the inquiry round 
table meeting focusing on AF detection and diagnosis. 
Discussions indicated that waiting times for access to 
diagnostic services in some areas could be up to eight 
or nine weeks. This is very problematic for patients who 
are at a very high risk of stroke and cannot commence 
anticoagulation to reduce that risk until their AF has been 
confirmed on a 12 lead ECG. 
Furthermore, consultation responses pointed out that  
longer term monitoring to detect paroxysmal AF could  
be particularly difficult to access. 
CASE STUDY
1 Encourage targeted AF case-finding programmes for those most at risk (age over 65 years, those with 
previous stroke and those 
with existing cardiovascular 
risk factors).
“Delays in obtaining diagnostic 
monitoring such as Holter 
(24 hour ECG) monitoring for 
those patients with suspected 
paroxysmal atrial fibrillation.”
This is particularly important when we consider that longer 
term monitoring can pick up AF in people who might not 
have it detected with shorter term monitoring. Access to 
these types of services is particularly crucial in secondary 
prevention of strokes related to AF.
Discussions at the round table meeting indicated that the 
two key issues underpinning this difficulty in accessing 
diagnostic services were a lack of financial resources within 
the NHS and a particular issue around staff resources. 
It was felt that the lack of financial resources presented a 
“catch-22 situation” as it inevitably has an impact on the 
staff resource, but also on the ability of the NHS to purchase 
newer, less time consuming technology which could reduce 
pressure on these services, and thus minimise the burden of 
these services on staff time. 
The specific staff resource issue highlighted during the 
round table discussion was that of a shortage of cardiac 
physiologists. These health care professionals are pivotal 
to the care of people with AF as they carry out and analyse 
cardiac tests, such as echocardiograms, 12 lead ECGs, 
24-hour ECGs etc. This issue was highlighted by the British 
Cardiovascular Society as far back as 2007.40 While this 
report focused on the UK workforce more broadly, it is clear 
from the feedback to the inquiry that this is an issue which 
is still relevant and has an important impact on services in 
Scotland. 
Consideration must be given to ways to overcome this issue. 
Examples of how to achieve this could be through workforce 
planning, developing appropriate training and ensuring 
multi-skilled health care staff. Furthermore, the utilisation 
of appropriate technology in order to relieve pressure on 
staff resources is another potential area for development. 
Finally, some respondents highlighted the importance of 
ensuring the application of Realistic Medicine principles in 
determining which patients are referred for services. These 
services should be utilised for patients at highest risk and 
who are likely to benefit from a change in management of 
their condition.
RECOMMENDATIONS 
The Scottish Government should
Image: Hand-held ECG device, image provided by AliveCor
A collaborative project involving NHS Lothian, 
Digital Health Institute (DHI), and Kardia 
evaluated the use of a hand-held single lead 
ECG device at scale in primary care. The study 
aimed to assess the potential benefits and 
cost-effectiveness of targeted, opportunistic 
case-finding for AF in a high risk population 
using a hand-held single lead ECG device, 
compared with usual care.
People with certain long-term conditions, 
including heart failure, diabetes and kidney 
disease were tested using the hand-held single 
lead ECG device when attending their practice 
for their annual long-term condition review. 
Five practices from each of five Scottish regions 
(Lothian, Greater Glasgow and Clyde, Tayside, 
Grampian, and Fife) took part in the study.
Although the device was able to detect AF 
effectively, the results were sent securely to local 
cardiology teams, who also verified diagnosis.
The study hoped to identify the yield of patients 
who might otherwise not be diagnosed using 
current methods and to propose a proven scalable 
solution for assessment of AF in Scotland.
The DHI funded a full economic review to identify 
savings from strokes avoided as well as required 
medication costs to prevent stroke. It was found 
that case-finding with the hand-held single lead 
ECG device cost £22.02 per patient, which was 
more cost effective than the base case analysis 
of usual care with no case-finding over a 30 year 
time horizon.
Preliminary results from the simulation model 
involved in this project indicate that a move 
to case-finding for AF in a high risk population 
using a hand-held single lead ECG device has the 
potential to be cost effective.39
AF CASE-FINDING IN PRIMARY CARE
2 Work with the relevant National Advisory Committees to address the shortage of cardiac 
physiologists working  
within Scotland.
3 Invest in the use of proven technologies within clinical practice to detect AF.
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Section Two:
Initial Treatment 
and Subsequent 
Management of 
Atrial Fibrillation
BACKGROUND 
As important as it is to improve detection and diagnosis of AF, it is vital that this 
coincides with appropriate post diagnosis pathways. Post diagnostic support 
involves appropriate education, treatment and follow-up.
There is currently no cure for most cases of AF. 
Guidelines from professional societies recommend  
that the first consideration when treating AF should  
be a decision on the need for anticoagulation 
medication to reduce the person’s risk of stroke. 
Anticoagulation
Anti-coagulation medication is a well evidenced way  
to reduce the risk of AF related strokes. 
Not everyone with AF has the same risk of stroke.  
The presence of certain factors increases the risk of an 
AF related stroke and this risk can be assessed using 
checklist scoring systems. The risk estimation tool that 
is recommended in Scotland is the CHA₂DS₂-VASc points 
system. Points are given if the person has any of the risk 
factors highlighted by the scoring tool shown to the right.
I think atrial fibrillation is unique to the individual so 
each case must be carefully considered to determine 
the correct course of treatment. It would be good 
if someone could give an idea of what treatments 
are available, and which are likely to work in each 
particular situation.
Richard (round table participant)
“ ”
CHA₂DS₂-VASc SCORE
SCORE
C Congestive Heart Failure / LV Dysfunction 1
H Hypertension 1
A Age ≥ 75 years 2
D Diabetes Mellitus 1
S Stroke (TIA / TE) 2
V Vascular Disease(a) 1
A Age 65 –74 years 1
S Sex (female) 1
a. Prior myocardial infarction, peripheral arterial disease, aortic plaque.
LV = left ventricular, TE = thromboembolism, TIA = transient ischemic attack
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SIGN Guidelines recommend that patients with AF who 
have a CHA₂DS₂-VASc score of 1 or above should be 
considered for anticoagulation.41 All patients with AF who 
have already had a stroke or TIA would have a high enough 
score to justify anticoagulation.
Anticoagulants work by increasing the time that the 
blood takes to clot, thus helping to reduce the risk of 
strokes caused by AF. Due to their effects on blood clotting, 
anticoagulants can cause bleeding complications. Decisions 
to start an anticoagulant need to balance the risk of stroke 
and the risk of bleeding. In the same way that clinical 
factors such as age and heart disease can be used to predict 
risk of stroke in AF, clinical factors can also be used to assess 
the risk of bleeding with anticoagulation. However, many 
of the things that can put someone at risk of bleeding 
with anticoagulation, for example high blood pressure and 
alcohol consumption, can be modified.
Warfarin is the most commonly prescribed anticoagulant 
and, when used appropriately, it’s an effective way of 
significantly reducing the risk of AF-related strokes, but it 
requires frequent blood tests and the dose often needs to be 
adjusted to ensure the medication is working as required.
The direct oral anticoagulants (DOACs) are a new class 
of anticoagulant drug. They are sometimes referred to as 
NOACs or non-vitamin K oral anticoagulants. They can be 
used in the prevention of stroke for people with AF, when 
the AF is not associated with certain heart valve problems. 
There are now four DOACs approved for use in NHS 
Scotland by the Scottish Medicines Consortium; Dabigatran, 
Rivaroxaban, Apixaban and Edoxaban. 
Large clinical trials have shown the DOACs to be similarly 
effective at preventing strokes as Warfarin.42-45 The main 
difference is that they are less influenced by diet and other 
medications. This means that a set dose can be prescribed 
and the doctor will know that the patient’s risk of stroke 
is reduced as long as the drug is taken. Patients do not 
require regular blood tests to check whether these drugs are 
working, as they do when on Warfarin, but they are required 
to be taken at the same time daily. A potential downside 
of this is that the process of monitoring can be a useful 
way to encourage medication compliance and present 
an opportunity for people taking an anticoagulant to get 
information about the drug from health care professionals. 
DOACs do have some limitations. For example, they 
have variable effects on routine coagulation tests which 
mean that if a person taking a DOAC has a major bleed 
or emergency surgery, then the amount of anticoagulant 
in their system is not easy to determine. Similarly, only 
one DOAC (Dabigatran) currently has a reversal agent 
available.46 Reversal agents for anticoagulation are used 
to reverse their effects on the blood in the case of serious 
bleeding or emergency surgery.
The introduction of DOACs has created space for patients  
to have more choice in the medication which best suits  
their needs. 
Heart rate and rhythm treatments
Some of the symptoms of AF, particularly palpitations, can 
be reduced through the use of medications to slow the heart 
rate. In some people with AF, medication, cardioversion 
(controlled electric shocks to the heart), or radiofrequency 
ablation (where energy is used to destroy the affected area 
of the heart causing the abnormal rhythm) can sometimes 
restore a normal heart rhythm in the short term. However, 
for older adults with other medical problems the AF often 
returns. These options are only suitable for those who have 
symptoms caused by AF. 
It is important to note that, while these interventions can 
improve symptoms and help people with AF feel better, 
anticoagulation remains the key intervention in reducing  
the risk of stroke. 
A number of respondents to the consultation highlighted 
that in Scotland there was a difficulty in referral for 
specialist assessment to identify those appropriate for 
cardioversion or ablation due to the availability of these 
services. Some respondents highlighted locally agreed 
protocols for referral to these services and suggested that 
perhaps a national protocol could be helpful.
INQUIRY FINDINGS — SUB OPTIMAL 
ANTICOAGULATION
Anticoagulation use for AF in Scotland is sub optimal.47,48
“Of the 284 patients seen in clinics with TIA or stroke with 
AF, only, 141 (50%) were on oral anticoagulants at the 
time of their event in 2016. Although, in many cases the 
AF may have been new, in many others this represents 
either a continued failure to identify patients with AF,  
or a failure to start patients on anticoagulants.”
— Scottish Stroke Care Audit49
Responses to the consultation questionnaire suggested that 
one of the key reasons for this was concern among clinicians 
about the risks associated with these medicines. 
“Fear among professionals of causing bleeding. Need to 
better inform doctors of the actual risks of bleeding on 
anticoagulants versus risks of ischaemic stroke.”
Navigating this risk decision is understandably difficult but 
a theme which emerged from the consultation responses 
and discussions at the round table meetings was that 
bleeding risk was often used as a reason not to prescribe 
anticoagulant medication when, in a number of cases, 
it should be used as a tool to modify risk factors (such 
as hypertension or alcohol consumption). A number of 
respondents mentioned that the risk of bleeding associated 
with falls was greatly over-estimated in clinical practice.
INQUIRY FINDINGS — ISSUES 
AROUND THE USE OF DIRECT ORAL 
ANTICOAGULANTS (DOACS)
Some responses to the consultation indicated that 
there could be a lack of awareness and confidence 
amongst some clinicians with regards to prescribing 
DOACs.
“Variation in where DOACs come in recommended 
treatment. Many GPs only offer Warfarin which the 
patient turns down, without realising that DOACs 
are available.” 
Other respondents to the consultation highlighted that 
it could be difficult to keep up with the evidence around 
these drugs. During the round table discussion on treatment 
and management of AF this was discussed in more detail 
with an agreement that, particularly in primary care, the 
option of choosing between five drugs (Warfarin and four 
DOACs) could be time consuming and had the potential to 
increase prescriber anxiety. It was suggested that support 
and education for health care professionals with regards to 
anticoagulants could be helpful in this regard.
Finally, a crucial barrier to the use of DOACs is financial 
limitations. Currently, DOACs are more expensive than 
Warfarin. There are variations in the guidance produced 
by different Health Boards with respect to which patients 
should be offered the new, and more expensive, oral 
anticoagulants. The round table discussions highlighted 
that this resulted in geographical variation in the availability 
of these medications. It was also highlighted at the 
round table discussion that there were often significant 
bureaucratic systems to adhere to in order to prescribe 
DOACs for patients. 
The purpose of the Scottish Medicines Consortium (SMC)  
is to accept for use those newly licensed medicines that 
clearly represent good value for money to NHS Scotland. 
The four DOACs mentioned above have been approved 
by the SMC.50-53 Discussions at the inquiry round table 
suggested that it seemed that NHS Scotland national policy 
and the policies of local Health Boards were disconnected.
APPROPRIATE USE OF 
ANTICOAGULATION REDUCES 
STROKE RISK IN AF BY 
TWO 
THIRDS
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One concern raised at the round table meetings with regards 
to a move away from Warfarin towards DOACs was the 
patient information and support given along with these 
drugs. Fairly robust pathways and patient information 
exists for Warfarin, and patients are recalled regularly for 
monitoring. It is important that patients continue to receive 
appropriate information and engage with appropriate 
health care professionals when they are prescribed DOACs. 
INQUIRY FINDINGS — NEED FOR 
INTEGRATED CARE FOR PEOPLE  
WITH ATRIAL FIBRILLATION
In response to a question on the co-ordination of care 
for people with AF, many professional responses to the 
inquiry consultation highlighted that either a GP or a 
specialist AF nurse should be responsible for this, with 
the best standard of care probably achieved by the two 
working together in an integrated way. 
“Few boards recruit arrhythmia nurses and I think this 
would improve the long term management of AF. If there 
was a dedicated specialist nurse they would have more 
time to develop pathways and local guidance documents 
to ensure regular follow up for AF patients.” 
AF requires long term condition management in a large 
population of patients. Therefore integrated care models 
that provide patient centred care while maintaining access 
to specialist treatment options are an appropriate approach 
to delivery of health care services to people with this 
condition. Such integrated care can be provided by multi-
disciplinary health care teams including pharmacists, nurses, 
GPs and cardiologists. 
Given the policy background of integration and multi-
disciplinary working discussed in the introduction to this 
report, such a pathway seems highly relevant. 
Two examples of integrated care were highlighted by a 
number of respondents to the inquiry consultation as 
examples of good practice. 
4 Work with stakeholders in primary and secondary care to create a clear and consistent clinical pathway for people diagnosed with AF.
RECOMMENDATIONS 
The Scottish Government should
5 Actively promote and support Health Boards to implement specialised AF services to facilitate accurate diagnosis; to ensure prompt, appropriate anticoagulation and to ensure 
patient-centred management.
In NHS Lanarkshire a nurse led atrial 
fibrillation clinic was set up in 2010. This  
clinic aimed to assess, investigate and 
manage patients with new onset AF, quickly 
and efficiently and ensure involvement in  
all decisions by patients and their families. 
The clinic was established utilising pre-existing 
resources within cardiology to streamline the 
pathway for existing patients. Crucially, the clinic 
received support from the cardiology department 
for investigations.
The first key goal was to address the need for 
anticoagulation to reduce patients’ risk of stroke 
by utilising the scoring system highlighted earlier 
in the document. The second was to improve 
the patients’ quality of life: by ensuring prompt 
initiation of medication, tailored to the patients’ 
symptoms and lifestyle. 
The clinic operated in a ‘one stop shop’ 
style where patients would have access to 
necessary assessment and treatment at the one 
appointment. An audit of patients’ experiences 
showed that 80% felt their results were explained 
in a way they could understand and 95% felt the 
standard of care received was excellent (65%) or 
very good (30%). 
The clinic also had an impact on anticoagulation 
rates, with an audit showing that the 66% of the 
clinic’s patients were anticoagulated (at only two 
weeks post diagnosis) in comparison to a national 
audit at the time which placed anticoagulation 
rates at 41%.
One strand of an integrated care project, 
initially funded by the British Heart 
Foundation, included reviewing current 
care provision for AF patients and setting 
up a rapid access nurse-led clinic for these 
patients in NHS Tayside. 
The programme also provided education and 
developed knowledge and skills in arrhythmia 
management for members of the wider health 
care teams within primary and secondary care. 
These education events were evaluated positively 
with most participants saying that they would 
recommend the event and that their post-course 
knowledge was substantially higher than  
pre-course. 
The impact of the project locally, and its potential 
transferability were robustly evaluated. Patients 
reported many positive outcomes relating to their 
experience, the ease of access to the service,
the degree to which they could manage their 
condition and the impact that this care had 
on their quality of life. In an evaluation of the 
service, 98% of respondents reported satisfaction 
with care provided by a nurse as opposed to 
another medical professional and 94% of 
respondents reported that the nurse had helped 
them understand their condition. This project  
has successfully been implemented, operating 
at full capacity and now sustained by the NHS 
Health Board.54
KEY OUTCOMES WERE;
–  Better working and sharing of information/skills 
across teams e.g. between nursing, medical staff 
and the physiologists; and integration between 
primary and secondary care teams.
–  Shorter waiting times, fewer cancellations and 
timely follow up allowing further intervention  
if required. 
– Improved patient experience.
CASE STUDY
NURSE LED INTEGRATED CARE FOR AF — NHS LANARKSHIRE
NURSE LED INTEGRATED CARE FOR AF — NHS TAYSIDE
Image: NHS Tayside nurses receiving an award from BHF
Nurse-led care has been shown to be very effective in the 
management of patients with AF, improving appropriate 
prescribing of anticoagulation treatment, appropriate 
application of rate and rhythm control therapies and 
patient understanding of the condition, all of which have 
been identified as issues by this inquiry. Cardiovascular 
hospitalisation rates and mortality were also shown to be 
lower in a nurse-led care model.55
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Section Three:
The Use of Data to 
Improve Detection, 
Diagnosis and 
Treatment of Atrial 
Fibrillation
BACKGROUND 
Health care professionals collect a variety of information during patient 
consultations. Information such as whether the patient smokes, any medicines 
prescribed and other tests or treatments the patient has had, are recorded and  
can be shared with other parts of the NHS to make sure that the person receives  
the appropriate treatment.
These data are also very useful for purposes beyond 
individual treatment. In Scotland every patient has 
a unique identifier, the Community Health Index 
(CHI) number, which is used to label every interaction 
they have with health care. The use of CHI numbers 
allows national records (births, deaths etc.) hospital, 
primary and social care information to be integrated 
for an individual across their lifetime. Some of this 
information is brought together and stored in national 
databases which are managed by the Information 
Services Division (ISD) Scotland on behalf of NHS 
Scotland. 
The Quality & Outcomes Framework (QOF) was an 
important source of data to estimate the prevalence of 
particular chronic conditions. It measured achievement 
by general practices against a range of evidence-based 
indicators. Participation by general practices in the QOF was 
voluntary and payments were made to each participating 
practice on the basis of points achieved against indicators.
QOF is being decommissioned in Scotland, and funding 
transferred to practice core funding. QOF data will no longer 
be extracted for payment purposes, although 2016–17 
QOF data was extracted to support the peer led GP Cluster 
Continuous Quality Improvement process as part of the 
latest General Medical Services contract agreement. Some 
respondents to the survey highlighted concerns about 
the effectiveness of data collection in the absence of the 
incentivisation from QOF.
There are massive 
opportunities for using 
national datasets but 
also many barriers  
to accessing these data. 
Dr Terry Quinn (advisory panel)
“ ”
Scottish Primary Care Information Resource (SPIRE) is the 
Scottish Government’s move to improve the way it uses 
information from patient records. It has been developed to 
help GPs, the NHS in Scotland and researchers learn from 
information held at GP practices and will be used to plan 
for Scotland’s health and care needs. The system allows 
information from GP patient records to be transferred 
electronically and held securely at NHS National Services 
Scotland. 
At the outset of this inquiry the members of the advisory 
panel were clear about the potential for data to have 
an impact on AF detection, diagnosis and treatment in 
Scotland. The inquiry consultation and subsequent round 
table meeting sought to identify areas of good practice and 
also the barriers to utilising data which exist in Scotland. 
INQUIRY FINDINGS — IMPROVEMENTS 
AT PRACTICE LEVEL NEEDED
A number of respondents to the consultation 
highlighted the need for software that allowed 
practice staff to better assess the needs of the practice 
population. This is important because practice level 
is where immediate changes and interventions can be 
made for people with AF, thus having a substantial 
impact.
A number of responses to the consultation highlighted two 
similar projects as examples of best practice in relation to 
data use to improve AF treatment.
Both projects utilised a practice software tool called GRASP-
AF. This is an electronic tool which runs a set of queries on 
the practice database building a list of every patient with 
a diagnosis of AF, the drugs associated with AF and any 
contraindications for anticoagulation.
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This project ran from 2012 until 2014 and was 
fully funded by the British Heart Foundation. 
Its primary aim was to improve the capability 
of staff in primary care settings to manage 
patients with AF. To achieve this, an audit of 
activity was conducted using the GRASP-AF 
tool. 
GRASP-AF ALLOWS THE PRACTICE TO; 
–  Calculate the risk of stroke in patients with  
AF using CHA₂DS₂-VASc scoring.
–  Identify patients at high risk of having a stroke 
who are not receiving anticoagulation.
–  Calculate the number of strokes that a practice 
can expect in the next 12 months, given current 
levels of anticoagulation.
 –  Help practices manage their patients with AF  
and highlight patients of concern or interest.
–  Provide a dashboard view that is easy to read  
and gives a graphical representation and 
'snapshot' of patient care.
 
On completion of the audit, practices were 
provided with a summary of the findings, and 
the health care professionals involved in the 
project made recommendations and provided 
CASE STUDY
THE USE OF GRASP-AF IN PRIMARY CARE — NHS LANARKSHIRE
tailored training for staff based on the findings. 
The project’s design involved the use of an “audit 
and education” approach focused on increasing 
the skills, knowledge and confidence of primary 
care staff to identify patients with AF, and to 
optimise their on-going management. The project 
team worked with 55 out of 96 GP practices in 
Lanarkshire, exceeding their original target. 
THE OUTCOMES WERE; 
–  The prevalence of AF increased: up to 1.68%  
of patients in the Health Board area from a  
1.4% baseline;
–  More high risk patients were on anticoagulation 
medication: 62.2% of high risk patients which is  
an increase of 4.2% from baseline; and,
–  The stroke risk reduced by 14% from baseline 
which meant 13 strokes saved in the first year.56 
Based on the success of that project NHS 
Greater Glasgow and Clyde (NHSGGC) 
developed a similar model led by their 
Managed Clinical Network and supported  
by the British Heart Foundation.
Starting in 2014, three quarters of GP practices 
in NHSGGC ran GRASP-AF software in order to 
undertake localised audit in each participating 
practice. 
Each practice was provided with a GRASP-AF 
summary dashboard which clearly showed their  
AF prevalence. The dashboard showed the 
CHA₂DS₂-VASc score including a percentage 
and actual patient numbers of people with AF 
according to their current medical management 
— prescribed an anticoagulant, antiplatelet,  
both or neither.
In addition to the audit tool, all practices involved 
were offered education sessions provided by a 
Clinical Development Coordinator employed by 
the British Heart Foundation. 
This work resulted in significant improvements 
in the management of patients with AF. 
Anticoagulation rates in high risk individuals 
rose from 57% to 71% over two years which is 
conservatively estimated to have saved 30 strokes 
per year across NHSGGC.
A crucial part of this process was the help 
received from primary care pharmacists and 
pharmacy support technicians to run the software 
in practices and produce the patient level detail 
for the GP. Without such support from pharmacy 
colleagues, the software was often not utilised to 
its full potential.
Image: GRASP-AF summary dashboard example, image provided by PRIMIS
THE USE OF GRASP-AF IN PRIMARY CARE — NHS LANARKSHIRE CONTINUED
THE USE OF GRASP-AF IN PRIMARY CARE — NHS GREATER GLASGOW & CLYDE
GRASP-AF is funded by the Department of Health England 
and therefore is freely available to practices within NHS 
England. Discussions at the inquiry round table meeting 
on the use of data were very supportive of a similar tool 
being developed as part of the SPIRE roll out. It was felt 
that this would be a crucial intervention which could have a 
significant impact on the prevention of AF related strokes. 
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RECOMMENDATIONS 
The Scottish Government should
6 Imbed consistent and effective data capture, ensuring integration across clinical boundaries of primary and secondary care and efficient processes 
for linking and accessing these data. 
7 Support the development and implementation of IT software solutions to facilitate case- finding, support therapeutic decisions and  allow audit within and between practices. 
INQUIRY FINDINGS — BARRIERS TO THE USE OF ‘BIG DATA’
Traditionally, AF research has been based on recruiting 
large numbers of participants into research studies 
and collecting information over several years. 
Improvements in Information Technology (IT) and the 
availability of large databases of clinical information 
potentially allow information to be collected for 
research at a national level.
The unique CHI identifier makes Scotland ideally placed for 
such ‘big data’ research. Combined patient data could be 
used to plan health care policy, monitor safety, ensure that 
drugs aren’t causing unexpected side effects, and improve 
the quality of health care by analysing how the health 
service is being run.
Although there have been exemplars of using routinely 
collected data to look at important questions in AF, such as 
the anticoagulation prescribing patterns in stroke survivors 
with AF, with particular emphasis on sociodemographic 
associations,57 such routinely collected data have not been 
used as often or as well as many would have hoped for. 
Throughout the course of the inquiry some general barriers 
were highlighted which might explain why this is the case. 
These included the time necessary to input data fully, 
concerns about confidentiality, the difficulty in ensuring 
accurate coding and disparate IT systems. In particular, 
attention was drawn to the disparity between systems at 
primary and secondary care levels. 
At the round table discussion on this topic it was highlighted 
that creating a cohort of AF patients for big data 
research projects requires using data from various records 
(hospitalisation, community prescribing records or Scottish 
Stroke Care Audit). These data sources do not allow for an 
identification of AF patients who are not anticoagulated, 
and who have not been hospitalised with either AF or a 
stroke. This is a major limitation for potential research into 
this condition.
Discussions at the round table meeting also highlighted that 
working with routine administrative data sources can be 
difficult due to long waiting times as several data custodians 
are involved to grant permission for data access. Linking the 
different data sources requires separate applications for 
data access. Those involved in such data usage expressed 
that their hope was for a more streamlined process available 
in the future.
Decisions and policy around AF should be based on the 
best available evidence and researchers have been using 
routinely recorded data in Scotland to look at effectiveness 
and cost effectiveness of various anticoagulant medications. 
One team, who had a lot of experience working in this area, 
appreciated the possibilities of using routine data for AF 
research but also noted challenges. For example, it was a 
struggle for them to include patients who had not been in 
contact with secondary care services. 
A more streamlined process, that still maintained data 
governance, would be a major step forward for AF research 
in Scotland. 
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Section Four:
The Views of People 
Living with Atrial 
Fibrillation
BACKGROUND
Cultural attitudes and policy direction in Scotland are increasingly focused on  
the need for patients and their carers to be involved in shared decision making 
around their healthcare.
In 2012 the Scottish Government published the Charter  
of Patient Rights and Responsibilities.58 A key theme 
in this document was around communication and 
participation in health care decisions. Furthermore, 
the Chief Medical Officer in Scotland is supportive of 
a cultural change towards “Realistic Medicine” which 
aims to build a personalised approach to care and a 
culture of shared decision making.
“When people are more involved in decisions, they  
are more likely to adhere to treatment, less likely to  
suffer the consequences of over-investigation and  
over-treatment and be more satisfied with their  
outcomes and relationship with their professionals.” 
— Realistic Medicine, p1759
With this in mind, the inquiry process set out to hear from 
people living with AF about their experiences and get their 
suggestions as to what worked well and what could have 
been better for them. These findings have been kept in mind 
throughout the development of all of the recommendations.
INQUIRY FINDINGS — INFORMATION 
PROVISION TO PEOPLE LIVING WITH 
ATRIAL FIBRILLATION
Living with a long-term condition such as AF can have 
a significant impact on those affected, including on the 
social, economic, psychological and physical aspects of 
their lives. In order to deal with this impact as best as 
possible, people need to have the information and skills 
to develop appropriate self-management strategies. 
Being able to access reliable information and support 
can empower people to learn about their condition and 
identify where changes could be made, or where they 
might need extra support.
The people living with AF who responded to our consultation 
highlighted accessing information about the condition 
and potential treatments as an area where they felt 
I probably had AF for a long time but didn’t 
know what it was. To me, the condition  
was unknown. 
Ivan (round table participant)“ ”
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improvements could be made. Of the 59 respondents to  
the patient questionnaire, 15% stated that they received  
no information at all about their condition while only 33% 
felt that they received a detailed explanation.
In particular, respondents highlighted a gap in information 
sharing with regards to whether they should have been 
given rate or rhythm control interventions such as 
cardioversion or ablation.
“I was advised by my GP that I was not a candidate for 
cardioversion or ablation, but he did not explain why.”
“I am angry that I was not told about a procedure called 
ablation (I think) until it was too late.”
“I would have been happier if it had been explained to  
me why other treatments were not for me.”
People living with AF who responded to the consultation 
were clear that receiving more information about the 
condition and their treatment options would have greatly 
improved their experience. Discussions at the round table 
confirmed this. Those who were happy with the care 
they received pointed to the flow of information and 
communication with their health care professionals as  
a factor crucial to their satisfaction. 
Clinician respondents to the consultation noted that, 
although anticoagulation for AF is usually a long-term 
medication, many patients were not taking their prescribed 
anticoagulant a few years after diagnosis. 
NICE guidelines highlight that non-adherence to medication 
should not be seen as the patient’s problem but that it 
represents a limitation in the delivery of healthcare, perhaps 
due to a failure to fully agree the prescription, provide 
the appropriate information or identify the support that 
patients require.60 
Addressing this requires more work to understand the 
patient experience and their reasons for continuing or 
stopping AF medications. At a clinical level, this highlights 
the importance of exploring the patient’s perspective and 
sharing information in a way that allows the patient to 
make informed decisions. 
It is clear that there is scope for thinking about how patient 
centred care and shared decision making principles can 
be applied in the context of AF. Specialist AF clinics, as 
highlighted earlier in this report, are one way to achieve 
the provision of personalised information and care for 
people with AF, and promote appropriate self-management 
strategies.
Many clinicians who responded to the consultation 
identified leaflets as a useful tool for sharing information 
with patients but only a small number of those living with 
AF who responded to the consultation (17%) recalled 
receiving anything like this.
In our round table discussion with people with AF, it was felt 
that leaflets had been helpful and played an important role. 
In particular, a need to ensure that information was reliable 
was expressed and many people pointed to publications 
from respected third sector organisations or NHS websites 
as sources of good information. The discussions highlighted 
that further to receiving leaflets, the critical aspect for most 
people was having contact with a health care professional 
who could answer any questions and tailor information to 
the person’s individual situation.
There are a number of other barriers to information 
provision such as language barriers, medical jargon and 
poor health literacy. Any efforts to improve information 
dissemination must take these into account.
INQUIRY FINDINGS — PEOPLE WITH 
ATRIAL FIBRILLATION FELT THAT THEY 
COULD BENEFIT FROM A REGULAR 
REVIEW OF THEIR CONDITION
A number of responses to the consultation indicated 
that review processes for people with AF are variable 
throughout Scotland. In some areas people with AF  
are reviewed regularly, while in other areas this does 
not seem to be the case. 
Responses from people living with AF indicated that a more 
regular review process would have improved many of their 
experiences.
“I would have liked a check-
up programme, perhaps six 
monthly. I have had little 
success in asking about drug 
changes and risks of current 
drugs.”
SIGN guideline 129 states that,
“The balance of risks and benefits of anticoagulant 
therapy should be assessed and discussed annually 
with the patient, with consideration given to patient 
preference.”61
The provision of integrated multi-disciplinary care can allow 
opportunities for patients to receive appropriate review 
of their condition. This could be provided by a variety of 
health care professionals depending on local staffing 
provision. This may involve nurses, pharmacists or cardiac 
physiologists.
Discussions at our round table meeting on treatment of 
AF highlighted that community pharmacy could have a 
particular role to play with regards to regular medication 
review of people with AF.
“Achieving Excellence in Pharmaceutical Care: A Strategy for 
Scotland”62 highlights the importance of the pharmaceutical 
workforce in delivering integrated, person centred care in 
Scotland. 
The strategy draws attention to the fact that work is 
ongoing to enhance the Pharmacy Care Record (PCR) in 
order to introduce an annual pharmacist-led medication 
review traditionally carried out by GPs. So perhaps there is 
scope to consider how AF would fit within this framework, 
as it was clear throughout the inquiry that this would be of 
great value to people with AF. 
INQUIRY FINDINGS — RAISING  
PUBLIC AWARENESS OF ATRIAL 
FIBRILLATION
A public health awareness campaign around AF was 
a common theme which arose from the consultation 
responses, both from clinicians and people living  
with AF.
“I think there needs to be more public awareness.  
So that people are aware of what it is.”
At the round table discussion on detection and diagnosis 
the merits of raising public awareness were discussed. It 
was thought to be helpful generally to raise awareness 
of the condition and its links to stroke amongst a general 
population, although it was felt that more detailed 
information such as how to check a pulse for example, was 
better shared through more targeted awareness raising to 
high risk groups. Some examples of projects which did this 
were shared with the group, including a project carried out 
in NHS Fife63 and one carried out in NHS Grampian which 
aimed to provide people attending cardiac rehabilitation 
with the skill to take their own pulse.64
It was also suggested that, just as important as raising 
public awareness, was raising awareness of AF among 
health care professionals. 
8 Ensure that all health care professionals have the necessary information about AF to support 
patients to take part in 
shared decision making, 
from the point of diagnosis 
of AF through to long term 
condition management.
RECOMMENDATIONS 
The Scottish Government should
9 Work with clinicians, researchers, third sector and people affected by AF to  
find the most  
effective methods  
to raise awareness  
of AF among the 
public.
10 Ensure that people with AF, and at risk of AF, receive relevant, tailored information 
and support, utilising 
robust and trusted 
providers such as 
major third sector 
charities.
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Glossary
 
A
Ablation — a treatment that aims to control or correct 
certain types of abnormal heart rhythms.
Anti-arrhythmic medications — medicines which aim to 
return the heart rhythm back to normal.
Anticoagulants — a group of medicines used to prevent 
harmful blood clots from forming.
Antithrombotic medication — drugs which reduce 
the formation of blood clots. There are two classes of 
antithrombotic drugs: anticoagulants and antiplatelets 
(such as aspirin). Aspirin is no longer recommended in the 
prevention of strokes associated with AF. 
Arrhythmia — an abnormal heart rhythm.
Atria — the upper chambers of the heart. 
Atrial Fibrillation — an irregular heart rate that increases 
the risk of stroke.
C 
Cardiac physiologist — health care professional who  
carries out cardiac tests, such as echocardiograms, ECGs, 
Holter monitors (24-hour ECG) etc. 
Cardiology — medical speciality relating to the diagnosis 
and treatment of heart disease.
Cardiovascular disease — includes all the diseases of the 
heart and circulation.
Cardioversion — involves using a defibrillator to give a 
controlled electric shock to get return the heart rhythm to 
normal.
Case-finding — a strategy used to identify patients with a 
certain condition.
Chronic kidney disease — a disease where the kidneys 
don't work as well as they should.
Chronic respiratory diseases — diseases of the airways and 
other structures of the lung.
Coagulation tests — measurement of how long a person’s 
blood takes to clot.
Cohort — a group of subjects with a common defining 
characteristic.
Community Health Index — a population register which is 
used in Scotland for health care purposes.
Contraindication — a condition or factor that serves as a 
reason to withhold a certain medical treatment due to the 
harm that it would cause the patient.
Coronary artery disease — a condition where the inside 
of the coronary arteries becomes narrowed because fatty 
deposits have built up within the artery walls.
 
D
Dementia — an umbrella term for a group of conditions 
that affect how well the brain can function. 
Demographic — characteristics of a given population.
Diabetes — a condition where the level of glucose (sugar)  
in the blood is too high. 
Direct oral anticoagulant — a newer class of 
anticoagulation medications.
 
E
Electrocardiograph — a test that gives information about 
the electrical activity of your heart. The ECG helps to 
identify the source of the abnormal rhythm. 
 
F
Fatigue — persistent feeling of tiredness.
 
G
GP — a primary care doctor.
 
H
Health boards — NHS Scotland consists of 14 regional 
NHS Boards which are responsible for the protection and 
the improvement of their population's health and for the 
delivery of frontline healthcare services and 7 Special NHS 
Boards and one public health body who support the regional 
NHS Boards by providing a range of important specialist and 
national services.
Heart attack — damage to a part of the heart muscle 
caused by a sudden loss of blood flow to a part of the heart. 
Heart failure — when the heart becomes less effective at 
pumping blood around the body.
Heart rate — how quickly the heart beats.
Heart rhythm — how regular or irregular the beats are.
High blood pressure — when the pressure of blood 
running through the arteries is too high (consistently 
over 140/90mmHg) it can have negative effects on the 
cardiovascular system. 
Holter monitoring — a technique involving continuous 
recording on an electrocardiogram (ECG) over 24 hours, 
or longer. The patient wears the device on a belt with 
electrodes attached to their chest. 
 
I
Ischaemic stroke — a stroke caused by a blockage cutting 
off the blood supply to the brain.
 
L
Left ventricular dysfunction — heart condition in which 
the heart is unable maintain normal function due to a 
problem in the left ventricle.
Long term condition — conditions for which there is 
currently no cure and which are managed with drugs and 
other treatment. 
 
M
Mortality — another word for death, when considered on a 
large scale.
 
O
Obesity — the term "obese" describes a person who's very 
overweight, with a lot of body fat.
 
P
Palpitations — the sensation of feeling your heartbeat 
sometimes described as a thumping or fluttering in  
the chest.
Prevalence — a statistical concept referring to the number 
of cases of a disease that are present in a particular 
population at a given time.
Primary care — health care provided in the community.  
It is usually the first point of contact for patients and 
involves providing care for common illnesses and long  
term conditions.
 
R
Radial pulse check — is the measurement of the pulse 
through the radial artery in the wrist.
Rate control — giving treatment to control the rate of the 
heartbeat, so that the heart beats more slowly, even if the 
heartbeat remains irregular.
Risk factor — something that increases your risk of 
developing a disease or condition.
Rhythm control — giving treatment to try to get the heart 
back to a normal rhythm.
 
S
Secondary care — medical care provided by a specialist, 
usually upon referral by primary care.
SIGN guidelines — Scottish Clinical guidelines which are 
developed statements to assist practitioner and patient 
decisions about appropriate health care for specific clinical 
circumstances by making recommendations for effective 
practice based on current evidence.
Sinus node — the heart’s natural pacemaker. Electrical 
impulses originate here and travel through the heart, 
causing it to beat.
Sleep apnoea — a condition where the walls of the 
throat relax and narrow during sleep, interrupting normal 
breathing.
Stroke — a stroke is a brain attack which happens when the 
blood supply to part of your brain is cut off. 
 
T
Thrombectomy — a treatment that removes a blood clot 
with a mechanical device. 
Thromboembolism — an obstruction to blood flow due  
to a blood clot in a deep vein, usually the legs (DVT) or  
the lungs (PE).
Thrombolysis — a process to that uses medication to 
dissolve a blood clot in the coronary arteries or in the 
arteries leading to the brain. 
Thyroid disease — a medical condition affecting the 
function of the thyroid gland. 
Transient Ischaemic Attack — is the same as a stroke, 
except that the symptoms only last for a short amount of 
time because the blockage that stops the blood getting to 
the brain is temporary.
 
V
Valvular heart disease — disease of the heart valves,  
which can affect the flow of blood, putting extra strain  
on the heart.
Vascular disease — disease of the blood vessels.
 
W
Warfarin — the most widely prescribed anticoagulant.  
It decreases the clotting ability of the blood, and so  
reduces the risk of blood clots forming.
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Appendix
Patient representatives 
Mr Jim Bruce 
Jim engages regularly with Chest, Heart & Stroke Scotland 
and has an interest in atrial fibrillation which led to him 
joining the advisory panel.
Mr Paul Hodson
Paul regularly volunteers for Chest, Heart & Stroke Scotland, 
sharing his lived experience of aphasia with health care 
professionals and other volunteers. He also sits on the Stroke 
Association UK Stroke Assembly Panel. His interest in atrial 
fibrillation led him to joining this advisory panel.
Third sector organisations
Ms Wendy Armitage
Community Engagement Manager, 
Chest Heart & Stroke Scotland
Wendy Armitage is a nurse with over 
20 years’ experience working within 
the NHS across primary and secondary 
care before moving into the Third 
sector. She has a special interest in the 
field of cardiology and community-
based support. 
Ms Morven Dunn
CVD Clinical Development Coordinator, 
British Heart Foundation Scotland 
Morven Dunn has over 20 years of 
cardiovascular nursing experience, 
including developing the first Scottish 
specialist AF clinic. For the last 4 years 
she has worked as part of the Health 
Services Engagement team at the 
British Heart Foundation.
Mr Colin Oliver
Head of Information and Awareness, 
Stroke Association
Colin Oliver is responsible for 
information on stroke and stroke-
related matters for the Stroke 
Association in Scotland.
Academic and clinical advisors
Dr Neil Grubb
Consultant in Cardiology and Cardiac 
Electrophysiology, NHS Lothian
Dr Neil Grubb is a Consultant 
in Cardiology and Cardiac 
Electrophysiology in NHS Lothian.  
He was the Principal Investigator for 
a Scottish national pilot screening for 
atrial fibrillation in primary care.
Professor Lis Neubeck
Professor and Head of Theme of the 
Long Term Conditions theme in the 
School of Health and Social Care at 
Edinburgh Napier University 
Professor Lis Neubeck is a 
cardiovascular nurse with more than 
20 years of clinical experience. Her 
research interests are in detection and 
patient-facing management of AF.  
She has led numerous research 
projects and published extensively  
on these topics.
Dr Terry Quinn
Stroke Association and Chief Scientist 
Office Senior Clinical Lecturer, 
Cardiovascular and Medical Sciences, 
University of Glasgow
Dr Terry Quinn holds the post of joint 
Chief Scientist and Stroke Association 
Senior Clinical Lecturer. He combines 
his program of research into stroke 
with his clinical and teaching work in 
the stroke units of Glasgow.
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The Secretariat for the Cross-Party 
Group on Heart Disease and Stroke is 
provided by British Heart Foundation 
Scotland, Chest, Heart & Stroke 
Scotland and Stroke Association.
